Amgen (NQ:AMGN)

403.04 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

72 73 Next >

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.

Via Benzinga

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗

September 03, 2025

Via Stocktwits

2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges

September 03, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

2 Profitable Stocks Worth Your Attention and 1 We Avoid

September 01, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

2 Dividend Stocks to Hold for the Next 10 Years ↗

August 28, 2025

These stocks offer more than just dividends.

Via The Motley Fool

Topics Economy

2 Large-Cap Stocks to Target This Week and 1 That Underwhelm

August 28, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Deep Dive Into Amgen Stock: Analyst Perspectives (9 Ratings) ↗

August 25, 2025

Via Benzinga

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade ↗

August 20, 2025

Some of the highest-yielding stocks in the Dow Jones Industrial Average index look like smart buys for income-seeking investors.

Via The Motley Fool

Topics Stocks

3 Dow Jones Stocks to Keep an Eye On

August 20, 2025

The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership...

Via StockStory

Topics Artificial Intelligence Stocks

Warren Buffett, Cathie Wood Share 2 Stock Investments In Common: Can You Guess What They Are? ↗

August 18, 2025

Cathie Wood looks for growth and companies on their way to big profits. Warren Buffett prefers looking for value and consistent profits. The two investors have two stock investments in common.

Via Benzinga

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS ↗

August 16, 2025

Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

Via Benzinga

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. ↗

August 16, 2025

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.

Via The Motley Fool

Topics Economy

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed. ↗

August 13, 2025

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Via Investor's Business Daily

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism

August 12, 2025

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to $9.18 billion. The company’s full-year revenue guidance of $35.5 billion at...

Via StockStory

Topics Artificial Intelligence

Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98...

Via MarketMinute

Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...

Via MarketMinute

Topics Economy

Amgen Stock Sinks As Market Eyes MariTide's Next Move ↗

August 06, 2025

Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key therapies.

Via Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗

August 06, 2025

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.

Via Benzinga

Topics Lawsuit

Wall Street Recovers, Apple Rallies 6% On $100-Billion Gov Manufacturing Investment: What's Moving Markets Wednesday? ↗

August 06, 2025

U.S. stocks rebounded sharply on Wednesday, fully erasing last Friday's losses, as upbeat corporate earnings and renewed investor optimism outweighed concerns over escalating trade tensions.

Via Benzinga

Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline ↗

August 06, 2025

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share.

Via Benzinga

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

August 06, 2025

Via Investor Brand Network

Topics Government

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

August 06, 2025

EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

AMGEN INC (NASDAQ:AMGN) Shows Strong Technical Breakout Potential with High Setup Rating ↗

August 06, 2025

AMGEN INC (AMGN) shows strong breakout potential with a Technical Rating of 7 and Setup Rating of 9, signaling bullish momentum and a tight consolidation pattern.

Via Chartmill

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country' ↗

August 06, 2025

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Via Benzinga

Topics Government World Trade

Amgen (AMGN) Q2 Profit Jumps 21% ↗

August 05, 2025

Via The Motley Fool

Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue

August 05, 2025

Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue...

Via StockStory

Amgen Inc (NASDAQ:AMGN) Surpasses Q2 2025 Earnings Estimates Despite Muted Market Reaction ↗

August 05, 2025

Amgen beats Q2 2025 earnings with $9.179B revenue and $6.02 EPS, but shares dip slightly as market reaction remains muted. CEO highlights growth in biosimilars and raised full-year guidance.

Via Chartmill

Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News? ↗

August 05, 2025

Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock into a breakout.

Via Investor's Business Daily

Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday? ↗

August 05, 2025

Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.

Via Benzinga

Topics Economy Government

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.